<DOC>
	<DOCNO>NCT00002534</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy bone marrow transplantation may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : Randomized phase III trial compare effectiveness bone marrow transplantation use untreated treat bone marrow treat patient acute leukemia first second remission .</brief_summary>
	<brief_title>Bone Marrow Transplantation Treating Patients With Acute Leukemia First Second Remission</brief_title>
	<detailed_description>OBJECTIVES : I . Compare efficacy T-cell-depleted v unmodified allogeneic marrow rescue regard disease-free survival , post-transplantation leukemic relapse rate , incidence severity graft-versus-host disease , quality engraftment hematopoietic reconstitution , immunoreconstitution follow transplantation patient acute leukemia first second remission . OUTLINE : This randomize study . Patients stratify accord disease ( acute lymphocytic leukemia ( ALL ) v acute myeloid leukemia ( AML ) , age ( 20 vs 20 ) . Patients randomize one two treatment arm . Patients age 5 nonrandomly assign Arm I age 55 nonrandomly assign Arm II . Arm I : Patients receive total body radiotherapy day -7 -4 follow cyclophosphamide IV day -3 -2 . Patients undergo allogeneic bone marrow transplantation ( ABMT ) IV 2-4 hour day 0 . Patients also receive standard graft v host disease prophylaxis cyclosporine methotrexate . Arm II : Patients receive total body radiotherapy day -9 -6 , thiotepa IV day -5 -4 , cyclophosphamide Arm I . Patients undergo T-cell deplete ABMT IV 15 minute day 0 . Patients age 15 receive bone marrow female donor age 30 male donor age also receive graft rejection prophylaxis consist antithymocyte globulin IV 6-8 hour day -5 -4 oral methylprednisolone twice daily day -5 -4 . Beginning 2 month follow transplantation , adult patient AML prior history CNS disease , adult patient ALL , pediatric patient ( ALL ANLL ) receive CNS leukemia prophylaxis cytarabine intrathecally diagnostic lumbar puncture monthly 5 month ( 1 year patient prior history CNS leukemia ) . PROJECTED ACCRUAL : A total 128 patient randomize . At anticipated accrual rate 35 patients/year , accrual expect complete 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Acute leukemia follow category : Histologically document ANLL first remission ( CR1 ) second remission ( CR2 ) Pediatric ANLL patient CR1 eligible provide enrolled protocol CCG2891 ALL CR1 present least 1 follow highrisk feature : WBC presentation great 50,000/mm3 ( 200,000/mm3 pediatric patient ) Hypoploidy measure flow cytometry Pseudodiploidy translocation ( 9 ; 22 ) , ( 4 ; 11 ) , ( 8 ; 14 ) CR achieve 4 week induction therapy ALL CR2 relapse bone marrow follow first remission regardless time relapse Acute biphenotypic leukemia ( mixed myeloid lymphoid lineage presentation ) CR1 CR2 , i.e. , patient classify lymphoblastic myeloblastic base FAB morphology histochemistry feature Adult acute undifferentiated leukemia ( evidence lymphoid myeloid differentiation ) CR1 CR2 Patients category analyze separately CR define evidence leukemia time transplantation document normocellular bone marrow aspirate contain 5 % blast 2 week prior cytoreduction Normal diagnostic LP Ommaya reservoir tap require 2 week prior start cytoreduction ALL patient ANLL patient risk CNS disease No extramedullary disease time transplantation HLAidentical , MLCcompatible relate donor require Donor must healthy willing undergo general anesthesia donation procedure For Tcell depletion , donor able volume 15 ml/kg patient body weight harvest safely PATIENT CHARACTERISTICS : Age : Any age ( 5 55 eligible randomization ) Performance status : Karnofsky ( Lansky ) 70100 % Life expectancy : Greater 8 week Hematopoietic : See Disease Characteristics Hepatic : Bilirubin le 1.5 mg/dl SGOT great 3 time upper limit normal ( ULN ) ( parameter stable least 4 week prior transplantation ) Renal : Creatinine le 2 time ULN stable least 4 week prior transplantation OR Creatinine clearance least 70 mL/min Cardiovascular : Fractional shortening great 28 % echocardiogram ( 2328 % FS increase response stress supine bicycle ergometer ) LVEF least 50 % echocardiogram MUGA Other : In good clinical condition time transplantation medical problem would significantly increase risk procedure No infection time transplantation Not pregnant nursing PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
</DOC>